TCL1 Expression Pattern and Its Prognostic Impact In Waldenström’s Macroglobulinemia
Lema R, Montrieul L, Tournilhac O et al.
Key Points:
T-cell leukemia/lymphoma 1 (TCL1) known to be coactivator of AKT and NF-KappaB, and expressed during early stages of lymphopoiesis.
Plays important role in pathogenesis of CLL, and high level of expression and linked to poor outcome in CLL.
Authors investigated TCL1A expression in WM.
Findings: TCL1A expression level in WM significantly higher than those found in MM and lower than those found in CLL.
TCL1(+) patients have poorer 3-year-PFS than TCL1(-)(32% versus 62% respectively, p=0.15).
Implications:
WM tumor cells express TCL1.
TCL1 seems associated with poor outcome.
View the original abstract on the ASH website.
